News Related to 12-Month Event-Free Survival

Related coverage linked through entity extraction aliases.

OS Therapies Advances OST-HER2 Regulatory Submissions for Osteosarcoma Treatment

Mar 09, 2026

OS Therapies progresses toward Accelerated Approval for OST-HER2 in osteosarcoma, with FDA elevating meeting status and global regulatory submissions on track for Q1 2026.

OS Therapies Advances OST-HER2 Toward Accelerated Approval with Elevated FDA Meeting Status

Mar 09, 2026

FDA elevated OS Therapies' Type D meeting to Type B pre-BLA meeting for OST-HER2 in osteosarcoma, signaling transition to Accelerated Approval discussions. Clinical data submission targeted for end of Q1 2026.